Zealand Pharma — Maj 2022
-
The iLet
Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes:The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale....
GlobeNewswire News Room (www.globenewswire.com)
-
*The trial achieved key primary and secondary endpoints, demonstrating improved outcomes over standard of care for people living with type 1 diabetes.
*The study population — 440 adults and children 6 years and older with type 1 diabetes — was more diverse and representative of the U.S. type 1 diabetes population than any previous pivotal trial of automated insulin delivery systems.
-
*The iLet
Bionic Pancreas is a pocket-sized, wearable, investigational medical device designed to autonomously determine and deliver insulin doses to control blood glucose levels in people with diabetes.*Dr. Steven J. Russell, principal investigator, presented the results from the multi-center randomized Insulin-Only Bionic Pancreas Pivotal Trial at Advanced
Technologies & Treatments for Diabetes (ATTD) on Saturday, April 30, 2022. -
REZOLUTE ANNOUNCES POSITIVE DATA FROM ITS PHASE 2B (RIZE) STUDY OF RZ358 IN PATIENTS WITH CONGENITAL HYPERINSULINISM:
En konkurrent men Zealand Pharma kommer dog med deres Fase 3 data her i 2. kvt.
-
Deres forsøg er et "Open-label trial":
-
Fornemt tak
-
Pæn interesse inden regnskab i næste uge - any news?
-
Kun i småtingsafdelingen. Kan se at Intomics hvis platform Zealand Pharma benytter er blevet solgt.
"Lyngby-virksomheden Intomics solgt til amerikansk selskab"
Lyngby-virksomheden Intomics solgt til amerikansk selskab
Intomics, der arbejder med bioinformatik samt foretager dataanalyse til medicinal- og biotekindustrien, er blevet opkøbt af det amerikanske konsulent- og servicefirma ZS.
(medwatch.dk)
-
"Zealand Pharma to leverage Intomics bioinformatics platform within peptide drug discovery and development process"
(June 10, 2020)
-
tak @exitnu
-
Zealand Pharma ændrer finansieringsaftale med Oberland Capital https://proinvestor.com/investornyt/821762/zealand-pharma-aendrer-finansieringsaftale-med-oberland-capital
-
Credit Suisse Group er gået under 5 % ejerskab
-
Q&A med Zealand Pharma med Adam Stensberg er d. 20. maj kl. 15. Stil gerne spørgsmål allerede nu.
-
fornemt, tak
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind